TD Asset Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$304M Sell
1,621,109
-344,426
-18% -$64.8M 0.26% 78
2026
Q1
$383M Buy
1,965,535
+1,409,114
+253% +$272M 0.31% 66
2025
Q4
$102M Buy
556,421
+11,615
+2% +$2.04M 0.08% 191
2025
Q3
$83.6M Buy
544,806
+90,636
+20% +$13.7M 0.07% 225
2025
Q2
$63.5M Sell
454,170
-99,925
-18% -$14M 0.05% 268
2025
Q1
$81.5M Sell
554,095
-81,368
-13% -$11.8M 0.08% 226
2024
Q4
$83.3M Sell
635,463
-27,440
-4% -$3.84M 0.07% 227
2024
Q3
$103M Sell
662,903
-90,311
-12% -$14.6M 0.09% 194
2024
Q2
$117M Sell
753,214
-15,491
-2% -$2.33M 0.11% 171
2024
Q1
$104M Buy
768,705
+60,938
+9% +$8.07M 0.1% 192
2023
Q4
$95.3M Sell
707,767
-245,680
-26% -$31.9M 0.09% 193
2023
Q3
$129M Buy
953,447
+260,752
+38% +$35.6M 0.16% 122
2023
Q2
$99.2M Sell
692,695
-72,790
-10% -$10.7M 0.11% 145
2023
Q1
$106M Sell
765,485
-43,488
-5% -$5.85M 0.13% 141
2022
Q4
$110M Sell
808,973
-361,787
-31% -$45.4M 0.14% 134
2022
Q3
$129M Buy
1,170,760
+147,819
+14% +$18.8M 0.16% 113
2022
Q2
$135M Buy
1,022,941
+189,555
+23% +$24.9M 0.16% 117
2022
Q1
$111M Buy
833,386
+8,956
+1% +$1.07M 0.1% 162
2021
Q4
$96M Buy
824,430
+265,298
+47% +$31.2M 0.08% 198
2021
Q3
$67.2M Buy
559,132
+64,086
+13% +$7.46M 0.07% 217
2021
Q2
$56.7M Buy
495,046
+93,043
+23% +$10.2M 0.06% 264
2021
Q1
$40M Buy
402,003
+112,609
+39% +$11.3M 0.04% 317
2020
Q4
$28.9M Buy
289,394
+10,613
+4% +$1.12M 0.04% 353
2020
Q3
$30.6M Sell
278,781
-12,465
-4% -$1.39M 0.04% 306
2020
Q2
$30.8M Buy
291,246
+32,066
+12% +$3.31M 0.04% 277
2020
Q1
$23.1M Buy
259,180
+9,809
+4% +$923K 0.04% 305
2019
Q4
$24.9M Sell
249,371
-31,647
-11% -$2.98M 0.04% 346
2019
Q3
$25.1M Sell
281,018
-71,289
-20% -$6.18M 0.04% 328
2019
Q2
$29.1M Sell
352,307
-29,678
-8% -$2.33M 0.04% 310
2019
Q1
$30.9M Sell
381,985
-45,757
-11% -$3.61M 0.05% 285
2018
Q4
$32.5M Sell
427,742
-70,564
-14% -$5.51M 0.06% 259
2018
Q3
$39.4M Sell
498,306
-33,825
-6% -$2.56M 0.06% 258
2018
Q2
$37.4M Buy
532,131
+2,678
+0.5% +$193K 0.06% 259
2018
Q1
$37M Buy
529,453
+2,448
+0.5% +$170K 0.06% 267
2017
Q4
$36.6M Buy
527,005
+76,366
+17% +$5.15M 0.05% 268
2017
Q3
$30.5M Sell
450,639
-2,203
-0.5% -$139K 0.05% 302
2017
Q2
$30.9M Buy
452,842
+2,710
+0.6% +$177K 0.05% 288
2017
Q1
$28M Sell
450,132
-2,827
-0.6% -$165K 0.04% 323
2016
Q4
$24.8M Buy
452,959
+77,204
+21% +$4.38M 0.04% 324
2016
Q3
$24.7M Buy
375,755
+72,546
+24% +$4.74M 0.04% 314
2016
Q2
$18.3M Buy
303,209
+20,630
+7% +$1.2M 0.03% 366
2016
Q1
$15.9M Buy
282,579
+22,753
+9% +$1.37M 0.03% 398
2015
Q4
$17.6M Buy
259,826
+12,781
+5% +$838K 0.04% 358
2015
Q3
$15.7M Sell
247,045
-113
-0% -$7.43K 0.03% 371
2015
Q2
$15.7M Buy
247,158
+80,866
+49% +$5.54M 0.03% 388
2015
Q1
$11.4M Buy
166,292
+65,858
+66% +$4.58M 0.02% 464
2014
Q4
$7.07M Buy
100,434
+19,087
+23% +$1.37M 0.01% 582
2014
Q3
$5.81M Buy
81,347
+20,831
+34% +$1.52M 0.01% 612
2014
Q2
$4.5M Sell
60,516
-105,947
-64% -$7.66M 0.01% 680
2014
Q1
$10.8M Sell
166,463
-8,199
-5% -$530K 0.02% 450
2013
Q4
$10.4M Buy
174,662
+24,075
+16% +$1.31M 0.02% 437
2013
Q3
$7.82M Buy
150,587
+141,163
+1,498% +$7.09M 0.02% 487
2013
Q2
$446K Buy
+9,424
New +$480K ﹤0.01% 951

Other funds holding AZN

TD Asset Management's AZN Position: Q2 2026 in Review

TD Asset Management reduced its AstraZeneca (AZN) stake by 18% in Q2 2026, selling an estimated $64.8M and leaving 1,621,109 shares worth $304M. The position accounts for 0.26% of the portfolio, ranked #78.

TD Asset Management first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $383M in Q1 2026. 1,253 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • TD Asset Management held 1,621,109 shares of AstraZeneca worth $304M as of Q2 2026.
  • TD Asset Management sold 344,426 AstraZeneca shares in Q2 2026, an estimated $64.8M.
  • AstraZeneca made up 0.26% of TD Asset Management's portfolio in Q2 2026, its #78 holding.
  • TD Asset Management first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • TD Asset Management's AstraZeneca position peaked at $383M in Q1 2026.
  • 1,253 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.